目次

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hypothyroidism - Overview
Hypothyroidism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hypothyroidism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hypothyroidism - Companies Involved in Therapeutics Development
AbbVie Inc
Diurnal Group Plc
Kashiv BioSciences LLC
Sention Therapeutics LLC
Spectrix Therapeutics LLC
Synthonics Inc
Takeda Pharmaceutical Co Ltd
Xeris Biopharma Holdings Inc
Hypothyroidism - Drug Profiles
(levothyroxine + liothyronine) - Drug Profile
Product Description
Mechanism Of Action
(levothyroxine sodium + liothyronine sodium) - Drug Profile
Product Description
Mechanism Of Action
Armour Thyroid - Drug Profile
Product Description
Mechanism Of Action
levothyroxine - Drug Profile
Product Description
Mechanism Of Action
liothyronine - Drug Profile
Product Description
Mechanism Of Action
liothyronine sodium SR - Drug Profile
Product Description
Mechanism Of Action
Modified Release Thyroid Hormone Formulation - Drug Profile
Product Description
Mechanism Of Action
parathyroid hormone - Drug Profile
Product Description
Mechanism Of Action
ST-1891 - Drug Profile
Product Description
Mechanism Of Action
Hypothyroidism - Dormant Projects
Hypothyroidism - Discontinued Products
Hypothyroidism - Product Development Milestones
Featured News & Press Releases
Sep 01, 2021: Xeris Pharmaceuticals completes enrollment of its phase 1 study of levothyroxine (XP-8121)
Aug 11, 2021: Xeris Pharmaceuticals announces FDA acceptance of its IND application for XeriSol Levothyroxine (XP-8121) for the treatment of hypothyroidism
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hypothyroidism, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hypothyroidism - Pipeline by AbbVie Inc, 2022
Hypothyroidism - Pipeline by Diurnal Group Plc, 2022
Hypothyroidism - Pipeline by Kashiv BioSciences LLC, 2022
Hypothyroidism - Pipeline by Sention Therapeutics LLC, 2022
Hypothyroidism - Pipeline by Spectrix Therapeutics LLC, 2022
Hypothyroidism - Pipeline by Synthonics Inc, 2022
Hypothyroidism - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Hypothyroidism - Pipeline by Xeris Biopharma Holdings Inc, 2022
Hypothyroidism - Dormant Projects, 2022
Hypothyroidism - Discontinued Products, 2022

List of Figures
Number of Products under Development for Hypothyroidism, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022